-

Shareholder Alert: Robbins LLP Reminds Investors NMC Health Plc (NMHLY) Sued for Misleading Shareholders

SAN DIEGO & ABU DHABI, United Arab Emirates--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP reminds investors that a purchaser of NMC Health Plc (OTC: NMHLY) filed a class action complaint against the Company for alleged violations of the Securities Exchange Act of 1934 between March 13, 2016 and March 10, 2020. NMC provides healthcare services in the United Arab Emirates, the United Kingdom, Spain, and internationally.

If you suffered a loss as a result of NMC's misconduct, click here.

NMC Health Plc (NMHLY) Accused of Misleading Shareholders

According to the complaint, from March 13, 2016 to March 6, 2019, NMC issued its annual reports for 2015, 2016, 2017, and 2018, each time affirming the Company's "conservative approach in risk taking" and its implementation of "controls and mitigation strategies in order to reduce those risks," and touting NMC's internal controls. However, on December 17, 2019, Muddy Waters Capital LLC published a report revealing that NMC had failed to disclose: (i) its lack of internal controls; (ii) (de facto) related party transactions; (iii) its true debt burden; (iv) its true cash-on-hand and asset values; and (v) its use of reverse factoring. Finally, on March 10, 2020, Financial Times and Bloomberg published articles entitled "NMC Health Discovers Almost $3 billion of Debt Hidden from is Board" and "Abu Dhabi Insurer Steps In to Help NMC Health Pay Salaries," respectively. As a result of all of these disclosures, NMC Health currently trades at around $1.20, representing a staggering 97% decline from its class period high of $53.03.

NMC Health Plc (NMHLY) Shareholders Have Legal Options

Contact us to learn more:
Leo Kandinov
(800) 350-6003
lkandinov@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. Click here to receive free alerts from Stock Watch when companies engage in wrongdoing.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

Robbins LLP

OTC Pink:NMHLY

Release Versions
$Cashtags

Contacts

Leo Kandinov
Robbins LLP
5040 Shoreham Place
San Diego, CA 92122
lkandinov@robbinsllp.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Regencell Bioscience Holdings Limited Class Action Reminder - Robbins LLP Encourages RGC Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025. Regencell is a purported early-stage bioscience company focused on the research, development, and commercialization of traditional Chinese medicine (“TCM”) for the treatment of attention-deficit/hyperactivity disorder (“ADHD”) and autis...

POET Technologies Inc. Class Action Reminder - Robbins LLP Encourages POET Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired POET Technologies Inc. (NASDAQ: POET) securities between April 1, 2026 and 8:57 A.M. ET on April 27, 2026. POET Technologies describes itself as a "design and development company offering photonic integrated packaging solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photoni...

Immutep Limited Class Action Reminder - Robbins LLP Encourages IMMP Investors to Contact the Firm for Information About Their Rights

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP is Investigating Allegations that Immutep Limited (IMMP) Misled Investors Regarding the Viability and Efficacy of its Drug CandidateOn May 5, 2026, a class action was filed on behalf of all investors who purchased or otherwise acquired Immutep Limited American Depository Receipts (NASDAQ: IMMP) between March 24, 2025 and March 12, 2026. Immutep is an Australian-based biotechnology company focused on developing Lymphocyte Activation Gene-3 (LAG-3) related i...
Back to Newsroom